drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific antibody)
drug_description
CD20xCD3 bispecific T-cell–engaging antibody that recruits and activates T cells via CD3 to kill CD20+ B cells.
nci_thesaurus_concept_id
C148486
nci_thesaurus_preferred_term
Glofitamab
nci_thesaurus_definition
A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.
drug_mesh_term
glofitamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
CD20xCD3 bispecific antibody that simultaneously binds CD20 on B cells and CD3 on T cells, crosslinking them to activate T-cell signaling and cytotoxicity, leading to targeted lysis of CD20-positive malignant B cells.
drug_name
Glofitamab
nct_id_drug_ref
NCT06047080